X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

VRCI

Verici Dx Shows Strong Momentum with Impressive Q1 Growth, Singer Capital Markets

Verici Dx reports strong Q1 growth with rising Tutivia adoption, expanding transplant centre reach and positive outlook from Singer Capital Markets research note...
GENF

Genflow Biosciences expands animal health partnerships for canine gene therapy review

Genflow Biosciences has signed additional confidentiality agreements with leading animal health companies to evaluate data from its canine SIRT6 gene therapy programme, following positive preliminary results...
Genflow Biosciences Plc

Biotechnology: A sector built around practical scientific innovation

Biotechnology turns biological science into practical products, creating investment opportunities shaped by innovation, risk and commercial execution...
GENF

Genflow Biosciences (LON:GENF) and the Breakthrough Promise of Gene Therapy in Childhood Blindness

Genflow Biosciences highlights gene therapy innovation after a child’s sight improves following treatment for rare inherited blindness...
Smith & Nephew plc

Smith & Nephew to host Surgeon Insights event in London

Smith & Nephew will host an investor event in London featuring US surgeons discussing innovation platforms across sports medicine, wound care, and orthopaedics, with presentations and Q&A sessions led by..
AstraZeneca

FDA approves AstraZeneca’s Saphnelo Pen for self-administration in SLE

AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative to IV infusion...
Genflow Biosciences Plc

Gene therapy enters a more practical phase for biotech tnvestors

Gene therapy is moving closer to practical use, with Genflow’s delivery strategy and rare disease focus offering investors a clearer view of how scientific progress may translate into commercial opportunity...
Hikma Pharmaceuticals plc

Hikma reports solid start to 2026, maintains full-year outlook

Ahead of its Annual General Meeting, Hikma said all three businesses are performing well, announced a device partnership to support its generic Ellipta programme, and confirmed its 2026 revenue and..
GENF

Genflow Biosciences’ Dr Eric Leire highlights funding, pipeline progress and near-term catalysts

CEO Dr. Eric Leire discusses progress across Genflow’s dog study, glaucoma and sarcopenia programmes, recent grant funding, large market opportunities and upcoming milestones, including clinical results, partnering discussions and patent..
Verici Dx Plc

Verici Dx gains commercial momentum as Tutivia adoption builds

Commercial uptake of Verici Dx’s Tutivia test is accelerating, giving investors firmer evidence that adoption and reimbursement momentum may now be building together...
Genflow Biosciences Plc

GenFlow Biosciences sharpens its longevity strategy

GenFlow Biosciences is making its longevity strategy more investable by backing the science with practical choices on manufacturing, platform design and regulatory progress...
AstraZeneca

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally well tolerated...
GSK

GSK wins China approval for Blenrep in previously treated multiple myeloma

The approval covers Blenrep plus bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma and is supported by phase III DREAMM-7 data showing progression-free and overall survival benefits...
GENF

Genflow Biosciences partners with Acuitas to advance SIRT6 mRNA programme

Genflow Biosciences has entered a fully funded collaboration with Acuitas Therapeutics to apply lipid nanoparticle delivery technology to its SIRT6 mRNA platform, supporting preclinical development for age-related diseases...

Physicians Capital: Why Dr. Conrad Ivie Believes Doctors Must Reclaim Ownership Before Burnout Wins (video)

Dr. Conrad Ivie breaks down why more physicians are burning out while owning less of the healthcare system they power. From building Tennessee’s largest orthopaedic group to launching Physicians Capital,..
Brava Health

Brava Health uses AI to transform patient data into real-time clinical insight, says Dr Michael Karch

Dr Michael Karch of Brava Health argues that clinician resistance to AI is often misread. The real issue is not opposition to technology, but concern about how it is framed..
VRCI

Verici Dx sees accelerating Tutivia adoption in Q1 2026 trading update

In its Q1 2026 trading update, Verici Dx reported a 34% year-on-year increase in Tutivia testing volumes, growing use across US transplant centres and continued confidence in commercial traction through..
GSK Plc

GSK adds pulmonary hypertension candidate HS235 through 35Pharma acquisition

GSK has closed its acquisition of 35Pharma, gaining HS235, a potential treatment for pulmonary hypertension that targets the activin receptor signalling pathway and is expected to enter proof-of-concept trials soon...
Brava Health

Operating room efficiency is emerging as a real investment issue

Healthcare providers are starting to treat operating room efficiency as a way to create capacity and improve performance, not just divide limited theatre time...
Oxford Biomedica Plc

Oxford Biomedica launches fast-track viral vector manufacturing service

Oxford Biomedica has introduced a fast-track development and manufacturing offering for AAV and lentiviral vectors, aiming to shorten the route to GMP manufacture and help biotech clients reach clinical milestones..

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

VRCI

Verici Dx Shows Strong Momentum with Impressive Q1 Growth, Singer Capital Markets

Verici Dx reports strong Q1 growth with rising Tutivia adoption, expanding transplant centre reach and positive outlook from Singer Capital Markets research note...
GENF

Genflow Biosciences expands animal health partnerships for canine gene therapy review

Genflow Biosciences has signed additional confidentiality agreements with leading animal health companies to evaluate data from its canine SIRT6 gene therapy programme, following positive preliminary results...
Genflow Biosciences Plc

Biotechnology: A sector built around practical scientific innovation

Biotechnology turns biological science into practical products, creating investment opportunities shaped by innovation, risk and commercial execution...
GENF

Genflow Biosciences (LON:GENF) and the Breakthrough Promise of Gene Therapy in Childhood Blindness

Genflow Biosciences highlights gene therapy innovation after a child’s sight improves following treatment for rare inherited blindness...
Smith & Nephew plc

Smith & Nephew to host Surgeon Insights event in London

Smith & Nephew will host an investor event in London featuring US surgeons discussing innovation platforms across sports medicine, wound care, and orthopaedics, with presentations and Q&A sessions led by company leadership...
AstraZeneca

FDA approves AstraZeneca’s Saphnelo Pen for self-administration in SLE

AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative to IV infusion...
Genflow Biosciences Plc

Gene therapy enters a more practical phase for biotech tnvestors

Gene therapy is moving closer to practical use, with Genflow’s delivery strategy and rare disease focus offering investors a clearer view of how scientific progress may translate into commercial opportunity...
Hikma Pharmaceuticals plc

Hikma reports solid start to 2026, maintains full-year outlook

Ahead of its Annual General Meeting, Hikma said all three businesses are performing well, announced a device partnership to support its generic Ellipta programme, and confirmed its 2026 revenue and profit guidance remains unchanged...
GENF

Genflow Biosciences’ Dr Eric Leire highlights funding, pipeline progress and near-term catalysts

CEO Dr. Eric Leire discusses progress across Genflow’s dog study, glaucoma and sarcopenia programmes, recent grant funding, large market opportunities and upcoming milestones, including clinical results, partnering discussions and patent developments...
Verici Dx Plc

Verici Dx gains commercial momentum as Tutivia adoption builds

Commercial uptake of Verici Dx’s Tutivia test is accelerating, giving investors firmer evidence that adoption and reimbursement momentum may now be building together...
Genflow Biosciences Plc

GenFlow Biosciences sharpens its longevity strategy

GenFlow Biosciences is making its longevity strategy more investable by backing the science with practical choices on manufacturing, platform design and regulatory progress...
AstraZeneca

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally well tolerated...
GSK

GSK wins China approval for Blenrep in previously treated multiple myeloma

The approval covers Blenrep plus bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma and is supported by phase III DREAMM-7 data showing progression-free and overall survival benefits...
GENF

Genflow Biosciences partners with Acuitas to advance SIRT6 mRNA programme

Genflow Biosciences has entered a fully funded collaboration with Acuitas Therapeutics to apply lipid nanoparticle delivery technology to its SIRT6 mRNA platform, supporting preclinical development for age-related diseases...

Physicians Capital: Why Dr. Conrad Ivie Believes Doctors Must Reclaim Ownership Before Burnout Wins (video)

Dr. Conrad Ivie breaks down why more physicians are burning out while owning less of the healthcare system they power. From building Tennessee’s largest orthopaedic group to launching Physicians Capital, he explains why real estate, financial fluency and long-term ownership are becoming essential for doctors who want more than income tied to time...
Brava Health

Brava Health uses AI to transform patient data into real-time clinical insight, says Dr Michael Karch

Dr Michael Karch of Brava Health argues that clinician resistance to AI is often misread. The real issue is not opposition to technology, but concern about how it is framed and applied in practice, with the strongest opportunities lying in tools that support judgment rather than replace it...
VRCI

Verici Dx sees accelerating Tutivia adoption in Q1 2026 trading update

In its Q1 2026 trading update, Verici Dx reported a 34% year-on-year increase in Tutivia testing volumes, growing use across US transplant centres and continued confidence in commercial traction through 2026...
GSK Plc

GSK adds pulmonary hypertension candidate HS235 through 35Pharma acquisition

GSK has closed its acquisition of 35Pharma, gaining HS235, a potential treatment for pulmonary hypertension that targets the activin receptor signalling pathway and is expected to enter proof-of-concept trials soon...
Brava Health

Operating room efficiency is emerging as a real investment issue

Healthcare providers are starting to treat operating room efficiency as a way to create capacity and improve performance, not just divide limited theatre time...
Oxford Biomedica Plc

Oxford Biomedica launches fast-track viral vector manufacturing service

Oxford Biomedica has introduced a fast-track development and manufacturing offering for AAV and lentiviral vectors, aiming to shorten the route to GMP manufacture and help biotech clients reach clinical milestones sooner...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple